Embracing a holistic approach to DKD, CVD and CRM comorbidities with empagliflozin
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
7 June, 2024
Valid for credit through:
6 June, 2025
CME accredited by:
7 June 2024 - 6 August 2024
Hong Kong College of Community Medicine - 1.0
The Hong Kong College of Pathologists - 1.0
Hong Kong College of Physicians - 1.0
CME accredited by:
7 June 2024 - 6 June 2025
Hong Kong Doctors Union - 1.0
Endorsed by:
Hong Kong Doctors Union
CRMSynced Forum is a professional, integrated educational platform for Hong Kong healthcare professionals to receive the latest updates on international guidelines for cardio-renal-metabolic disease and related information, such as case reports, insightful articles and lectures. The platform includes interviews with numerous key opinion leaders (KOLs) in the field, from whom local healthcare professionals can gain valuable insights.
About the programme
The cardiovascular, renal, and metabolic (CRM) systems are interconnected through complex and multifactorial interaction and neurohormonal feedback mechanisms. In this webinar, Dr. Janaka Karalliedde from the Guy’s and St Thomas’ Hospital, King’s College London, the United Kingdom, highlights the significance of recognizing and addressing all three conditions, type 2 diabetes mellitus (T2D), diabetic kidney disease (DKD) and heart failure (HF), as well as the impact of empagliflozin on renal outcomes, cardiovascular benefits and mortality risks.
Dr. Karalliedde further emphasized the need for early intervention and the role of primary care physicians in screening and treating patients early with sodium-glucose cotransporter 2 inhibitors (SGLT2is) such as empagliflozin to maximize the potential benefits of the drug on the CRM systems and patients’ quality of life.
Dr. Janaka Karalliedde
Guy’s and St Thomas’ Hospital,
King’s College London,
United Kingdom
Disclaimer
This is an independent editorial article, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.